Artificial Intelligence-Enabled Quality by Design and Regulatory Science for Apixaban Orodispersible Tablets: A Critical Review of Clinical Rationale, Formulation Strategy, and Submission-Ready Documentation for Stroke Prevention
International Journal of Research in Pharmacy and Allied Science · 2026 · 05 (03) · 87-112
DOI: 10.71431/ijrpas.2026.5307 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Research in Pharmacy and Allied Science, 2026. Verfasst von Gururaj S Kulkarni und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Stroke is a leading global cause of death and acquired disability, affecting millions annually. Among post-stroke patients, 36–51% experience oropharyngeal dysphagia, rendering conventional film-coated tablets of apixaban – a direct factor Xa inhibitor – difficult or unsafe to administer. This review critically examines the evidence base for developing an apixaban Orodispersible Tablet (ODT) formulation across three converging domains: (1) global stroke burden and dysphagia-related adherence barriers in dysphagic, geriatric, and paediatric populations; (2) apixaban's biopharmaceutical constraints – particularly poor aqueous solubility (~40 µg/mL) and BCS Class II/IV designation – mapped onto ODT manufacturing approaches (direct compression, lyophilisation, sublimation) and excipient selection strategies; and (3) the integration of Artificial Intelligence (AI) within a formal Quality by Design (QbD) framework, detailing how Artificial Neural Networks (ANNs) and Genetic Algorithms (GAs) can optimise Critical Quality Attributes and resolve multi-objective formulation trade-offs. The review further maps AI-generated data streams onto eCTD Modules 2, 3, and 5 in alignment with FDA, EMA, and ICH requirements for data integrity (ALCOA+), model lifecycle management, and audit trail compliance.
Zitieren
APA
Kulkarni, G. S., N, M., & Balaji, A. (2026). Artificial Intelligence-Enabled Quality by Design and Regulatory Science for Apixaban Orodispersible Tablets: A Critical Review of Clinical Rationale, Formulation Strategy, and Submission-Ready Documentation for Stroke Prevention. International Journal of Research in Pharmacy and Allied Science, 05(03), 87-112. https://doi.org/10.71431/ijrpas.2026.5307
Vancouver
Kulkarni GS, N M, Balaji A. Artificial Intelligence-Enabled Quality by Design and Regulatory Science for Apixaban Orodispersible Tablets: A Critical Review of Clinical Rationale, Formulation Strategy, and Submission-Ready Documentation for Stroke Prevention. International Journal of Research in Pharmacy and Allied Science. 2026;05(03):87-112. doi:10.71431/ijrpas.2026.5307
BibTeX
@article{Kulkarni2026,
author = {Kulkarni, Gururaj S and N, Mithun and Balaji, Anna},
title = {Artificial Intelligence-Enabled Quality by Design and Regulatory Science for Apixaban Orodispersible Tablets: A Critical Review of Clinical Rationale, Formulation Strategy, and Submission-Ready Documentation for Stroke Prevention},
journal = {International Journal of Research in Pharmacy and Allied Science},
year = {2026},
volume = {05},
number = {03},
pages = {87--112},
doi = {10.71431/ijrpas.2026.5307}
}
EUVIMED